Cargando…

The impact of differences in viral entry and trafficking on the mechanism of HIV-1 neutralization

Detalles Bibliográficos
Autores principales:	Cincotta, CD Macedo, Wieczorek, LM, Barrows, B, Brown, B, Asher, L, Michael, N, Marovich, M, Polonis, VR
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442047/ http://dx.doi.org/10.1186/1742-4690-9-S2-P58

Ejemplares similares

P04-22. Multispecific monoclonal antibodies bind to primary human macrophages and induce the production of protective chemokines, MIP-1α and MIP-1β
por: Weaver, KL, et al.
Publicado: (2009)

Neutralization and enhancement of trans infection by erythrocyte-bound HIV with antibodies and complement
por: Beck, Z, et al.
Publicado: (2012)

P04-23. HIV-1 neutralization is impacted by the PBMC donor used for both virus growth and target cells, and the effects are neutralization reagent-specific
por: Wieczorek, L, et al.
Publicado: (2009)

Cross-clade neutralization of HIV-1 by a monoclonal antibody obtained by immunization with liposomes containing lipid A and a synthetic MPER peptide
por: Matyas, GR, et al.
Publicado: (2012)

P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays
por: Brown, BK, et al.
Publicado: (2009)

P04-19. Analysis of the binding of multiple clades of HIV-1 by a modified virus capture assay
por: Peachman, K, et al.
Publicado: (2009)

Immunogenic selection of HIV-1 MPER epitopes for improved vaccine design
por: Wieczorek, L, et al.
Publicado: (2012)

P05-04. Neutralizing antibodies induced by immunization with liposomal gp41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes
por: Matyas, GR, et al.
Publicado: (2009)

P19-41. Full-length IMC expressing Renilla luciferase for neutralization assay using PBMC
por: Chenine, A, et al.
Publicado: (2009)

P04-28. Breadth and magnitude of neutralizing antibody responses in subjects infected with HIV-1 subtype D or recombinants in Rakai district, Uganda
por: Eller, L, et al.
Publicado: (2009)

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
por: Joachim, A, et al.
Publicado: (2012)

Antigenicity and immunogenicity of a novel, acute HIV-1 Tanzanian subtype C gp145 envelope protein for clinical development
por: Polonis, V, et al.
Publicado: (2012)

Soluble and bacteriophage T4 displayed gp41 mutant proteins as HIV-1 vaccine candidates
por: Gao, G, et al.
Publicado: (2012)

PRO 2000, a broadly active anti-HIV sulfonated compound, inhibits viral entry by multiple mechanisms
por: Huskens, Dana, et al.
Publicado: (2010)

P04-40. Dissecting pre- and post-attachment activity of HIV-1 entry inhibitors and neutralizing antibodies
por: Berlinger, L, et al.
Publicado: (2009)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
por: Lynch, RM, et al.
Publicado: (2012)

Analysis of gp41 epitopes in model viral membranes to study HIV-1 neutralization
por: Reichart, T, et al.
Publicado: (2012)

The interaction of HIV-1 and HIV-2 with cellular protein trafficking pathways
por: Alford, Justine, et al.
Publicado: (2013)

Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus
por: Mayr, LM, et al.
Publicado: (2012)

The Role of Natural Killer (NK) Cells and NK Cell Receptor Polymorphisms in the Assessment of HIV-1 Neutralization
por: Brown, Bruce K., et al.
Publicado: (2012)

Orally HIV-1 exposed uninfected men who have sex with men display HIV-neutralizing capacity correlating with their partners viral load
por: Hasselrot, Klara
Publicado: (2006)

Recognition and penetration of the HIV-1 Env glycan shield by potent broadly neutralizing antibodies
por: Julien, J, et al.
Publicado: (2012)

P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group
por: Scarlatti, G, et al.
Publicado: (2009)

Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection
por: Wieczorek, Lindsay, et al.
Publicado: (2022)

Conformation-dependent recognition of HIV Gp120 by DARPins provides novel possibilities to develop distinct HIV entry inhibitors
por: Mann, AM, et al.
Publicado: (2012)

Pre-existing humoral immunity in military smallpox vaccinees temporally effects MVA-vectored transgene expression in dendritic cells
por: Ngauy, V, et al.
Publicado: (2012)

V5 region in the HIV-1 envelope glycoprotein determines viral sensitivity to the broadly neutralizing monoclonal antibody VRC01
por: Guo, D, et al.
Publicado: (2012)

Glyconanoparticles as a platform to multimerize peptides involved in HIV entry process
por: Di Gianvincenzo, Paolo, et al.
Publicado: (2011)

Early immune events during acute HIV infection
por: Slike, BM, et al.
Publicado: (2012)

P09-12. Autologous neutralizing antibodies in early subtype C HIV-1 infection target variable regions of envelope and drive multiple pathways of viral escape
por: Rong, R, et al.
Publicado: (2009)

P04-46. Broadly cross-neutralizing activity in plasma of HIV-1 and HIV-2 infected individuals
por: Fenyö, E, et al.
Publicado: (2009)

P09-02. Selection pressure of neutralizing antibodies and viral escape continues in late stages of the disease
por: Rusert, P, et al.
Publicado: (2009)

P13-06. DARPin-based microbicide strategies to block HIV entry
por: Mann, A, et al.
Publicado: (2009)

P14-03. HIV-specific T-lymphocyte proliferative responses induced by a multigene multiclade HIV-1 DNA/MVA heterologous vaccine in Tanzanian volunteers
por: Aboud, S, et al.
Publicado: (2009)

The orally bioavailable allosteric CXCR4 HIV-1 entry inhibitor AMD11070
por: Fricker, Simon, et al.
Publicado: (2012)

Env mutations conferring improved entry efficiency allow HIV to replicate in the presence of IFN
por: Rato, Sylvie, et al.
Publicado: (2013)

P04-52 LB. The importance of well-defined HIV-1 neutralization assays
por: Balla-Jhagjhoorsingh, SS, et al.
Publicado: (2009)

Construction of SHIVs expressing quaternary neutralization epitopes in Env and mimicking the neutralization phenotype of typical HIV-1 isolates
por: Theis, JF, et al.
Publicado: (2012)

Systemic administration of a broadly-neutralizing IgG antibody to generate HIV-neutralization responses in breast milk
por: Fouda, GG, et al.
Publicado: (2012)

P04-53 LB. Potent and broad HIV-specific neutralizing antibodies in infants are not associated with prevention of mother to infant HIV transmission
por: Lynch, J, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_jbagkmbk5c6ukbeps3bfj9r730